List view / Grid view
20 May 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company and AbbVie announced that the U.S. Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone...
20 May 2014 | By Boehringer Ingelheim
Data analyses presented at the Annual American Thoracic Society International Conference 2014 reconfirm the efficacy of SPIRIVA® (tiotropium) in reducing the risk of COPD exacerbations...
20 May 2014 | By AstraZeneca
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal, comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014...
20 May 2014 | By Novartis
Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States...
Scientists analyzing non-conductive, high-purity materials will soon be able to apply powerful high-resolution glow discharge mass spectrometry (GDMS) to this task. This will open the technique, for example, to analysis of high-purity sapphire used for flat panel displays, ceramics, alumina powder and other desirable applications, including thin-layer depth profiling of…
19 May 2014 | By Roche
Roche announced plans to invest a total of 120 million Swiss francs in the construction of new production facilities in Building 50, an existing building at its Basel site...
19 May 2014 | By Janssen Pharmaceutical Companies
Janssen-Cilag International NV today announced that its next generation protease inhibitor OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C...
19 May 2014 | By The European Medicines Agency
The European Medicines Agency’s Committee for Advanced Therapies and the German Society for Transfusion Medicine and Immunohaematology in collaboration with the German Stem Cell Network are organising a workshop to strengthen dialogue...
19 May 2014 | By AbbVie
AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development and Chief Scientific Officer...
19 May 2014 | By Boehringer Ingelheim
Results from the Phase III INPULSIS™ trials, published online in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in patients with idiopathic pulmonary fibrosis...
16 May 2014 | By Pfizer
Public health initiative aims to increase unacceptably low adult vaccination rates...
16 May 2014 | By Novo Nordisk
Results from the SCALE™ Obesity and Pre-diabetes phase 3a trial will be presented on 16 May, 2014 for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists...
16 May 2014 | By Novartis
Novartis announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License Application for RLX030...
16 May 2014 | By Abbott
Abbott enhances its position in fast-growing Latin American market, more than doubling its branded generics pharmaceutical sales and presence in the region...
15 May 2014 | By Enigma Diagnostics
Enigma Diagnostics Ltd announced a collaboration agreement with China’s National Institute for Communicable Disease Control and Prevention, China Center for Disease Control and Prevention...
